- Home
- WINT vs SXTC Comparison
WINT vs SXTC Comparison
Compare WINT & SXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- SXTC
- Stock Information
- Founded
- WINT 1992
- SXTC 2005
- Country
- WINT United States
- SXTC China
- Employees
- WINT N/A
- SXTC N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- SXTC Biotechnology: Pharmaceutical Preparations
- Sector
- WINT Health Care
- SXTC Health Care
- Exchange
- WINT Nasdaq
- SXTC Nasdaq
- Market Cap
- WINT 2.0M
- SXTC 1.7M
- IPO Year
- WINT 1995
- SXTC 2019
- Fundamental
- Price
- WINT $0.12
- SXTC $0.40
- Analyst Decision
- WINT Hold
- SXTC
- Analyst Count
- WINT 1
- SXTC 0
- Target Price
- WINT $7.00
- SXTC N/A
- AVG Volume (30 Days)
- WINT 7.3M
- SXTC 561.3K
- Earning Date
- WINT 11-27-2024
- SXTC 01-01-0001
- Dividend Yield
- WINT N/A
- SXTC N/A
- EPS Growth
- WINT N/A
- SXTC N/A
- EPS
- WINT N/A
- SXTC N/A
- Revenue
- WINT N/A
- SXTC $1,928,497.00
- Revenue This Year
- WINT N/A
- SXTC N/A
- Revenue Next Year
- WINT N/A
- SXTC N/A
- P/E Ratio
- WINT N/A
- SXTC N/A
- Revenue Growth
- WINT N/A
- SXTC N/A
- 52 Week Low
- WINT $0.11
- SXTC $0.30
- 52 Week High
- WINT $14.75
- SXTC $3.37
- Technical
- Relative Strength Index (RSI)
- WINT 15.60
- SXTC 44.99
- Support Level
- WINT $0.21
- SXTC $0.39
- Resistance Level
- WINT $0.33
- SXTC $0.45
- Average True Range (ATR)
- WINT 0.03
- SXTC 0.04
- MACD
- WINT 0.00
- SXTC -0.00
- Stochastic Oscillator
- WINT 2.15
- SXTC 33.63
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About SXTC China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.